Current reports
22/2023
06.09.2023 17:09
Subject matter: Mabion enters into an agreement for the manufacture and delivery of a direct packaging leakage check and optical inspection line to the Company’s manufacturing facility
20/2023
31.07.2023 21:06
Information update on the loan agreement with the European Bank for Reconstruction and Development
19/2023
11.07.2023 14:47
Conclusion of an agreement for the supply of bioreactor set to the Company’s manufacturing facility
18/2023
13.06.2023 17:41
List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company after the meeting resumed on 13 June 2023.
List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment
17/2023
13.06.2023 17:34
Contents of resolutions put to the vote at the Ordinary General Meeting of Mabion S.A. after the meeting resumed on 13 June 2023
Contents of the resolutions put to the vote at the general meeting of Mabion S.A. held on 13 June 2023
16/2023
07.06.2023 18:42
List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company on 7 June 2023 until the adjournment
List of shareholders holding at least 5% of the number of votes at the Ordinary General Meeting of Mabion S.A. on 7 June 2023 until the adjournment
15/2023
07.06.2023 18:40
Appointment of Members of the Supervisory Board for the 3rd joint term of office
14/2023
07.06.2023 18:38
Adjournment of the Ordinary General Meeting of Mabion S.A. and content of resolutions adopted until the adjournment
Remuneration policy for members of the management board and supervisory board of Mabion S.A. with its registered office in Konstantynów Łódzki
12/2023
24.05.2023 12:41
Mabion receives as a notice of candidacy for a Member of the Company’s Supervisory Board
11/2023
22.05.2023 17:26
Conclusion of an annex to the agreement for the supply of bioreactors to the Company’s manufacturing facility
10/2023
22.05.2023 08:52
The Company terminates its agreement with Parexel for the clinical trial of MabionCD20
9/2023
11.05.2023 19:08
Notice convening the Annual General Meeting of Mabion S.A. for 7 June 2023, together with draft resolutions
7/2023
18.04.2023 05:18
Mabion S.A. adopts the Company Strategy for 2023–2027 and discloses delayed confidential information on the adoption of the strategy’s initial framework assumptions
5/2023
06.04.2023 11:33
Mabion signs annex with Novavax, Inc. for the manufacture of COVID-19 vaccine antigen, Omicron variant
2/2023
06.02.2023 15:21
Mabion signs a loan agreement for USD 15,000,000 with the European Bank for Reconstruction and Development
36/2022
13.12.2022 14:31
KDPW’s statement on the assimilation of the Company’s S series ordinary bearer shares
35/2022
12.12.2022 12:43
Admission and introduction of the Company’s S series ordinary bearer shares to stock exchange trading
33/2022
26.10.2022 22:21
The Company terminates the co-financing agreement for the project “Expansion of the Research and Development Centre of Mabion S.A. – research on a new generation of medicines”
32/2022
18.10.2022 15:55
Credit Committee of the European Bank for Reconstruction and Development approves financing for the Company
31/2022
22.09.2022 23:40
Broadening and extension of cooperation with Novavax, Inc. – Omicron variant
29/2022
30.08.2022 14:32
Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase
28/2022
24.08.2022 16:26
Statement of the Central Securities Depository of Poland on the registration of the Company’s S series shares
27/2022
08.08.2022 14:09
Summary of the subscription of the Company’s S series ordinary bearer shares carried out as part of the Incentive Scheme for 2021
20/2022
21.06.2022 18:26
List of shareholders holding at least 5% of the votes at the Annual General Meeting of the Company on 21 June 2022.
19/2022
21.06.2022 18:20
Contents of the resolutions of the Annual General Meeting of Mabion S.A. of 21 June 2022.
17/2022
28.05.2022 13:09
Extension of the scope of services under of manufacturing agreement with Novavax
16/2022
25.05.2022 19:47
Appointment of Members of the Management Board of Mabion S.A. for the second joint term of office
15/2022
15/2022
Notice of convening the Ordinary General Meeting of Mabion S.A. for 21 June 2022, together with draft resolutions
13/2022
21.04.2022 23:38
KDPW’s statement on the assimilation of S series ordinary bearer shares of the Company
12/2022
20.04.2022 15:02
Admission and introduction of S series ordinary bearer shares of the Company to stock exchange trading
11/2022
19.04.2022 17:03
Registration of the Company as the manufacturer of the SARS-CoV-2 rS active substance in the Register of the Chief Pharmaceutical Inspectorate
10/2022
19.04.2022 14:07
Conclusion of an annex to the agreement on co-financing of the project entitled “Expansion of the Research and Development Centre of Mabion S.A. – research on the new generation of medicines”
08/2022
02.03.2022 15:21
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities
07/2022
24.02.2022 08:34
Decision to abandon further implementation of the research project on the development of MabionEGFR
06/2022
14.02.2022 15:02
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
05/2022
31.01.2022 17:27
Allotment of shares and increase of the Company’s share capital as part of a conditional share capital increase
04/2022
18.01.2022 17:21
Announcement of the National Depository of Securities (Krajowy Depozyt Papierów Wartościowych S.A.) concerning the registration of S series shares of the Company.
03/2022
18.01.2022 17:15
Mabion receives an additional order to provide analytical product quality control services under manufacturing agreement with Novavax, Inc.
02/2022
14.01.2022 08:22
Mabion receives an additional order for the production of cellular banks under the manufacturing agreement with Novavax, Inc.
70/2021
Notification of transactionson Mabion S.A.’s shares performed by a person discharging managerial responsibilities.
69/2021
Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with reumatoid arthritis in Ukraine.
68/2021
Subscription summary for the Company’s S series ordinary bearer shares as part of the Incentive Scheme for 2020.
67/2021
An addendum to Current Report no. 26/2021 containing information on the completed subscription of U series shares issued by Mabion S.A.
64/2021
Mabion enters into an agreement for the supply of four bioreactors to the Company’s manufacturing facility.
61/2021
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
60/2021
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
59/2021
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
58/2021
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
57/2021
Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Belgium.
55/2021
Notification of transactions in Mabion S.A. shares carried out by a person discharging managerial responsibilities.
54/2021
Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Georgia.
53/2021
Mabion obtains authorisation to conduct a bridging clinical trial of MabionCD20 in patients with rheumatoid arthritis in Poland.
52/2021
Information on the execution of a commercial manufacturing agreement with Novavax, Inc. for the period of 2022-2025
49/2021
Adoption of a joint work programme for the marketing authorisation of MabionCD20 in the European and US markets and elaboration of the final data and clinical trial scope for the registration application on the European market.
48/2021
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
46/2021
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial resposibilities.
44/2021
List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 22, 2021
43/2021
Appointment of a Member of the Company’s Supervisory Board. Appointment of a Member of the Company’s Supervisory Board
42/2021
The content of the resolutions of the Ordinary General Meeting of Mabion S.A. of 22 June 2021
40/2021
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
39/2021
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities.
38/2021
Receipt of a motion to supplement the agenda of the General Meeting and a candidacy for Member of the Supervisory Board
37/2021
Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 22, 2021, alongside with draft resolutions
36/2021/K
Changes in the composition of the Company’s Management Board and Supervisory Board – correction of the numbering of the Current Report of 13 May 2021.
34/2021
Admission and introduction of ordinary bearer series U shares of the Company to stock exchange trading
33/2021
The conditional registration of series U shares of the Company with the National Depository for Securities
30/2021
Information on the performance of the first order under a framework agreement with Novavax, Inc.
28/2021
Admission and introduction of the rights to ordinary bearerseries U shares of the Company to exchange trading
25/2021
Cancellation of the Extraordinary General Meeting of MabionS.A. called for 22nd March 2021 and information on the review of the Company’s financing strategy
24/2021
Notifications about transactions on Mabion S.A. shares made by persons closely related to persons discharging managerial responsibilities in the Company
22/2021
Notification of transactions on Mabion S.A. shares performed bythe person discharging managerial responsibilities
21/2021
Determination of the issue price of new Series U shares issued by MabionS.A. and the final number of series U shares to be offered by the Company
20/2021
Information on declarations of particular shareholderssubmitted in connection with the book-building process
19/2021
Mabion S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription ofnew Series U ordinary bearer shares issued by Mabion S.A.
17/2021
Notification of transactions on Mabion S.A. shares performed by the person discharging managerial responsibilities
15/2021
Entering into a master service agreement with the first work order with Novavax Inc. for contract services related to the COVID-19 vaccine program
14/2021
List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on February 23, 2021
12/2021
Content of resolutions of the Extraordinary General Meeting of Mabion S.A. of 23 February 2021
11/2021
Announcement on the convening of the Extraordinary General Meeting of Mabion S.A. of March 22, 2021 together with draft resolutions
4/2021
Announcement on convening the Extraordinary General Meeting ofMabion S.A. on February 23, 2021, alongside with draft resolutions
3/2021
Decision on commencing activities aimed at attracting astrategic investor for the Company and on two planned issues of the Company’s shares
2/2021
Assignment of Supervisory Board member to perform the duties of a member of the Management Board
48/2020
Statement of the National Depository for Securities S.A. concerning: the conditional registration of series S shares with the National Depository for Securities
47/2020
The fifth summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
45/2020
Update of information regarding the Company’s cooperation with Vaxine Pty Ltd. regarding a potential Covid-19 vaccine
44/2020
The fourth summons to shareholders of Mabion S.A. forsubmitting the share documents in the Company’s registered office
43/2020
The third summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
42/2020
Updated information concerning the Company’s cooperation with Vaxine Pty Ltd. in scope of a potential Covid-19 vaccine
41/2020
Conclusion of an agreement with Parexel to conduct the final clinical trial before submitting a marketing authorisation application for MabionCD20 to the European Medicines Agency (EMA)
40/2020
Signing of the initial understanding in scope of cooperation covering research, development, and commercialisation of the antibodies of drug MabionCD20 in specific clinical indications concerning rare diseases.
38/2020
The second summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
37/2020
Signing of a Letter of Intent (LoI) on development work and production of the “IL-1R7 Antibody”, developed as a possible medication to treat Covid-19 infections.
36/2020
The first summons to shareholders of Mabion S.A. for submitting the share documents in the Company’s registered office
34/2020
Conclusion of Memorandum of Understanding on potential cooperation regarding a product that may be a vaccine for Covid-19 disease
32/2020
Information regarding a meeting with the US Food and Drug Administration (FDA) concerning registration and marketing authorization for MabionCD20 drug on the territory of the USA.
29/2020
Information on initial assumptions regarding the renewed Marketing Authorization Application to be filed for MabionCD20
28/2020
Receipt of a written response from the European Medicines Agency as a part of the ‘Scientific Advice’ regarding the assumptions for the new registration process for MabionCD20
27/2020
Summary of the subscription of S series ordinary bearer shares of the Company carried out under the Incentive Scheme for 2019
26/2020
Satisfaction of the condition of the permit to conduct business activity in the Łódź Special Economic Zone.
25/2020
List of shareholders holding at least 5% of votes at the Ordinary General Meetingof the Company on June 15, 2020.
22/2020
Announcement on convening the Ordinary General Meeting of Mabion S.A. on June 15, 2020, along with draft resolutions
21/2020
Decision on the intention to issue U series ordinary bearer shares of the Company in order to increasethe share capital of Mabion S.A.
16/2020
Arrangements for financing the Company’s operations in light of the new regulatory strategy for registration of MabionCD20 in the EMA
14/2020
Resignation of a Member of the Supervisory Board of the Company and appointment of President of the Management Board of the Company
13/2020
Update on the registration procedure for the marketing authorisation of MabionCD20 by the European Medicines Agency
12/2020
Receipt of a summary of a BPD Type 3 meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA
11/2020
Receipt of the list of issues to be presented at the meeting of the Committee for Medicinal Products for Human Use to be held on 24-27 February 2020
10/2020
Change of the building permit for Mabion S.A. Science and Technology Centre for Advanced Medical Biotechnology in Konstantynów Łódzki.
7/2020
Submitting answers to the questions as part of the registration procedure for MabionCD20 with the European Medicines Agency
4/2020
Information regarding a Type 3 BPD meeting with the Food and Drug Administration (FDA) on the registration and marketing authorisation of MabionCD20 in the USA
3/2020
Declaration of the National Depository for Securities (KDPW) on conditional registration of P and S series shares in the KDPW
38/2019
Receipt of the summary from the CHMP meeting regarding the registration procedure of the MabionCD20 drug.
37/2019
Update of information concerning the registration of drug MabionCD20 for marketing authorisation and disclosure of delayed confidential information.
36/2019
Obtaining approval on extension of the research project deadline from the National Centre for Research and Development.
35/2019
Registration of conditional increase of share capital and amendment to the Articles os Association.
34/2019
List of shareholders holding at least 5% of votes at the Extraordinary General Meeting of the Company on November 29, 2019.
33/2019
Summary of the subscription of the Company’s ordinary series S bearer shares carried out as part of the implementation of the Incentive Program for 2018.
32/2019
Contents of resolutions adopted by the Extraordinary Meeting of Shareholders of Mabion S.A. on 29 November 2019.
31/2019
Notifications about transactions on Mabion S.A. financial instruments made by a person discharging managerial responsibilities.
30/2019
Submission of answers to the Company’s Duplicate application for registration of MabionCD20 with the European Medicines Agency.
29/2019
Responses to round two of inquiries in scope of the registration procedure of MabionCD20 in the European Medicines Agency.
28/2019
Notice of convening the Extraordinary General Meeting of Mabion S.A. to be held on November 29, 2019, with draft resolutions attached.
27/2019
Appointment of BPD Type 3 meeting with the US Food and Drug Administration_FDA_concerning registration and marketing authorisation for the drug MabionCD20 within the territory of the United States.
26/2019
Agreement reached on the terms and conditions of and a decision made to conclude finance documentation with the European Investment Bank.
25/2019
Obtaining the GMP certificate for the Complex in Konstantynow Lodzki in the field of manufacturing a medicinal product.
22/2019
Information from the European Medicines Agency on the assessment of the results of GMP inspection related to MabionCD20 production in the complex in Konstantynów Łódzki.
21/2019
Mabion S.A. obtains the GMP certificate for the complex in Konstantynów Łódzki for the production of the production of the active substance.
20/2019
Receipt of the second round of questions in the MabionCD20 registration procedure at the European Medicines Agency.
18/2019/K
List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019. – correction
18/2019
List of shareholders holding at least 5% of votes at the Ordinary General Meeting of the Company on June 18, 2019.
16/2019
Implementation of the last condition of permission for conducting the operation in the Lodz Special Economic Zone at the Scientific and Industrial Complex of Medical Biotechnology in Konstantynow Lodzki.
15/2019
The acceptance of the second registration application for MabionCD20 drug for assessment by the European Medicines Agency.
14/2019
Notice of convening the Ordinary General Meeting of Mabion S.A. to be held on June 18, 2019, with draft resolutions attached.
13/2019
The submission of the second registration application concerning MabionCD20 drug to the European Medicines Agency.
11/2019
Resignation from the function of President of the Company’s Management Board.
10/2019/K
Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency – report correction.
10/2019
Submission of answers as part of the registration procedure for MabionCD20 at the European Medicines Agency.
5/2019
Fulfilment of the condition stipulated in the permit for conducting economic activity in the area of the Lodz Special Economic Zone at the Medical and Biotechnology Complex in Konstantynow Lodzki.
4/2019
Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities
3/2019
Notification about transactions on Mabion S.A. shares made by a person closely associated with a person fulfilling managing responsibilities